Lifecore Biomedical Inc. (LFCR)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $243.36M
Last updated: Nov 17, 2026 at 11:03 AM ET
Lifecore Biomedical Inc. (LFCR) Earnings: Report Dates and Results
Lifecore Biomedical (LFCR) is expected to report earnings on Feb 5, 2027. In the quarter ended Aug 31, 2026, Lifecore Biomedical reported EPS of -$1.08, below the -$0.30 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LFCR has an expected report date of Feb 5, 2027.
LFCR Earnings Call
The latest LFCR earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 38 quarters below that had an estimate, LFCR beat 11, missed 21 and matched 6. The widest gap in the table came in the quarter ended May 31, 2021, when EPS landed 800.00% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | -$1.08 | -$0.30 | N/A | -260.00% | Miss | N/A | N/A | N/A | Nov 4, 2026 | N/A |
| May 31, 2026 | -$0.19 | -$0.17 | N/A | -11.76% | Miss | N/A | N/A | N/A | Aug 5, 2026 | N/A |
| Feb 28, 2026 | -$0.16 | -$0.23 | N/A | +30.43% | Beat | N/A | 1 | 0 up, 1 down | Mar 16, 2026 | $23.19M |
| Nov 30, 2025 | Not reported | -$0.16 | N/A | N/A | Not reported | N/A | 1 | 0 up, 1 down | Jan 1, 2026 | $34.17M |
| Aug 31, 2025 | -$0.43 | -$0.30 | -$0.34 - -$0.28 | -43.33% | Miss | N/A | 4 | 0 up, 1 down | Nov 6, 2025 | $23.19M |
| May 31, 2025 | -$0.10 | -$0.09 | -$0.10 - -$0.09 | -11.11% | Miss | N/A | 2 | 0 up, 2 down | Aug 7, 2025 | $36.44M |
| Feb 28, 2025 | -$0.47 | -$0.15 | -$0.16 - -$0.14 | -213.33% | Miss | -211.9% | 2 | 2 up, 1 down | Apr 3, 2025 | $35.15M |
| Nov 30, 2024 | -$0.20 | -$0.30 | -$0.34 - -$0.27 | +33.33% | Beat | N/A | 2 | 0 up, 1 down | Jan 2, 2025 | $32.56M |
| Aug 31, 2024 | -$0.37 | -$0.46 | -$0.47 - -$0.46 | +19.57% | Beat | N/A | 2 | 0 up, 0 down | Oct 4, 2024 | $24.70M |
| May 31, 2024 | -$0.17 | -$0.12 | -$0.12 - -$0.12 | -41.67% | Miss | N/A | 1 | 0 up, 0 down | Aug 26, 2024 | $37.88M |
| Feb 29, 2024 | $0.42 | $0.13 | N/A | +223.08% | Beat | N/A | N/A | N/A | May 22, 2024 | $35.70M |
| Nov 30, 2023 | -$0.13 | -$0.23 | N/A | +43.48% | Beat | N/A | 2 | 0 up, 0 down | Dec 29, 2023 | $30.15M |
| Aug 31, 2023 | -$1.19 | -$0.23 | -$0.39 - -$0.13 | -418.13% | Miss | N/A | 2 | 0 up, 0 down | Nov 14, 2023 | $24.52M |
| May 31, 2023 | -$0.11 | -$0.07 | -$0.82 - $0.07 | -57.14% | Miss | N/A | 2 | 0 up, 0 down | Jun 1, 2023 | $31.14M |
| Feb 28, 2023 | -$0.42 | -$0.11 | N/A | -281.82% | Miss | N/A | 1 | 0 up, 0 down | Mar 16, 2023 | $26.54M |
| Nov 30, 2022 | -$0.21 | -$0.04 | -$0.06 - -$0.02 | -425.00% | Miss | N/A | 2 | 0 up, 0 down | Feb 27, 2023 | $21.86M |
| Aug 31, 2022 | -$0.32 | -$0.13 | N/A | -146.15% | Miss | N/A | N/A | N/A | Oct 6, 2022 | $23.72M |
| May 31, 2022 | -$0.01 | -$0.01 | N/A | 0.00% | In line | -114.3% | N/A | N/A | Aug 10, 2022 | N/A |
| Feb 28, 2022 | -$0.08 | -$0.03 | N/A | -166.67% | Miss | N/A | N/A | N/A | Apr 5, 2022 | $37.40M |
| Nov 30, 2021 | -$0.22 | -$0.09 | N/A | -144.44% | Miss | -1200.0% | N/A | N/A | Jan 5, 2022 | $43.45M |
| Aug 31, 2021 | -$0.23 | -$0.12 | N/A | -91.67% | Miss | N/A | N/A | N/A | Sep 29, 2021 | $43.35M |
| May 31, 2021 | $0.07 | -$0.01 | N/A | +800.00% | Beat | +40.0% | N/A | N/A | Jul 28, 2021 | N/A |
| Feb 28, 2021 | -$0.19 | $0.04 | N/A | -575.00% | Miss | N/A | N/A | N/A | Apr 7, 2021 | $44.69M |
| Nov 30, 2020 | $0.02 | $0.03 | N/A | -33.33% | Miss | N/A | N/A | N/A | Jan 6, 2021 | $130.90M |
| Aug 31, 2020 | -$0.38 | -$0.13 | N/A | -192.31% | Miss | N/A | N/A | N/A | Oct 6, 2020 | $135.64M |
| May 31, 2020 | $0.05 | $0.03 | N/A | +66.67% | Beat | N/A | N/A | N/A | Aug 11, 2020 | N/A |
| Feb 29, 2020 | -$0.39 | -$0.01 | N/A | N/A | N/A | -1075.0% | N/A | N/A | Mar 31, 2020 | $152.93M |
| Nov 30, 2019 | -$0.16 | -$0.06 | N/A | -166.67% | Miss | N/A | N/A | N/A | Jan 2, 2020 | $142.59M |
| Aug 31, 2019 | -$0.16 | -$0.16 | N/A | 0.00% | In line | -1700.0% | N/A | N/A | Oct 1, 2019 | $138.71M |
| May 31, 2019 | -$0.01 | -$0.02 | N/A | +50.00% | Beat | -104.2% | N/A | N/A | Jul 30, 2019 | $152.78M |
| Feb 28, 2019 | $0.04 | $0.05 | N/A | -20.00% | Miss | -55.6% | N/A | N/A | Apr 3, 2019 | $155.55M |
| Nov 30, 2018 | -$0.02 | -$0.02 | N/A | 0.00% | In line | -200.0% | N/A | N/A | Jan 3, 2019 | $124.56M |
| Aug 31, 2018 | $0.01 | $0.06 | N/A | -83.33% | Miss | -87.5% | N/A | N/A | Oct 2, 2018 | $124.67M |
| May 31, 2018 | $0.24 | $0.22 | N/A | +9.09% | Beat | +166.7% | N/A | N/A | Jul 31, 2018 | $141.08M |
| Feb 28, 2018 | $0.09 | $0.09 | N/A | 0.00% | In line | -50.0% | N/A | N/A | Apr 3, 2018 | $144.91M |
| Nov 30, 2017 | $0.02 | $0.01 | N/A | +100.00% | Beat | -60.0% | N/A | N/A | Jan 3, 2018 | $122.46M |
| Aug 31, 2017 | $0.08 | $0.06 | N/A | +33.33% | Beat | -33.3% | N/A | N/A | Sep 26, 2017 | $115.78M |
| May 31, 2017 | $0.09 | $0.09 | N/A | 0.00% | In line | -47.1% | N/A | N/A | Jul 25, 2017 | $64.95M |
| Feb 28, 2017 | $0.18 | $0.18 | N/A | 0.00% | In line | N/A | N/A | N/A | Apr 4, 2017 | $136.57M |
| Nov 30, 2016 | $0.05 | $0.06 | N/A | -16.67% | Miss | -28.6% | N/A | N/A | Jan 4, 2017 | $135.87M |
Annual EPS
EPS for the fiscal year ended May 31, 2026 was -$0.78, after -$1.14 the year before. It was $0.44 for the year ended May 31, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| May 31, 2026 | -$0.78 | N/A |
| May 31, 2025 | -$1.14 | N/A |
| May 31, 2024 | -$1.07 | N/A |
| May 31, 2023 | -$1.06 | N/A |
| May 31, 2022 | -$0.54 | N/A |
| May 31, 2021 | -$0.48 | N/A |
| May 31, 2020 | -$0.66 | -3400.0% |
| May 31, 2019 | $0.02 | -95.3% |
| May 31, 2018 | $0.43 | N/A |
| May 31, 2017 | $0.44 | N/A |
Earnings Calls
The 6 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 4,900 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 4,854 | 9 | |
| 2025Q4 | Dec 31, 2025 | 6,378 | 9 | |
| 2025Q3 | Sep 30, 2025 | 4,127 | 6 | |
| 2025Q2 | Jun 30, 2025 | 4,412 | 7 | |
| 2025Q1 | Mar 31, 2025 | 3,897 | 7 | |
| 2024Q4 | Dec 31, 2024 | 3,978 | 6 |
2026Q2 Earnings Call
Opening remarks
Stephanie Diaz Manager of Investor Relations Good morning, and thank you for joining us. Today, Lifecore Biomedical will provide its earnings results for the second quarter and 6 months ended June 30, 2026, and a corporate update. As the company has recently changed its fiscal year end to align with the calendar year, we will be comparing our results for the second quarter ended June 30, 2026, with the comparable prior year quarter ended May 25, 2025. For the 6-month period, we will be comparing our results from January 1 through June 30, 2026, with the prior year period from November 24, 2024, through May 25, 2025. Hosting the call today from Lifecore are Paul Josephs, President and Chief Executive Officer; and Ryan Lake, Chief Financial Officer. Before we begin, I'd like to remind everyone that today's conference call will contain forward-looking statements. It is important to note that the forward-looking statements made during this call reflect management's judgment and analysis only as of today, August 5, 2026, and the company's actual results could differ materially from those projected in such forward-looking statements. For a more thorough discussion of the risks and uncertainties associated with any forward-looking statements, please see the disclaimer regarding forward-looking statements that is included in our earnings press release, which was furnished to the Securities and Exchange Commission this morning on Form 8-K and is available on our corporate website at lifecore.com as well as our other filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-Q for Q2 2026, which was filed with the SEC this morning and is also available on our website. In addition, our earnings press release includes a discussion of, and during this call we will reference, certain non-GAAP financial information. You can find relevant non-GAAP reconciliations in our press release. With that, I'd like to turn the call over to Paul Josephs, President and Chief Executive Officer.
Paul Josephs President and Chief Executive Officer Thank you, Stephanie. Good morning, everyone, and thank you for joining us today. During the second quarter, Lifecore continued to execute with focus and discipline against the strategic objectives we implemented over the last 24 months. We are energized by the success and progress we are making in achieving the three pillars of our growth strategy. As a reminder, these pillars are maximizing our existing commercial business, advancing our development pipeline towards commercialization and adding high-quality new programs to our pipeline through business development. This is a thoughtful and deliberate strategy that is designed to drive durable growth over the medium to long term and create value for our shareholders as well as our employees, customers and other key stakeholders.
Frequently Asked Questions About LFCR
When is Lifecore Biomedical's next earnings date?
Lifecore Biomedical's next earnings report is expected for Feb 5, 2027.
Did LFCR beat earnings estimates last quarter?
No. Lifecore Biomedical reported EPS of -$1.08 for the quarter ended Aug 31, 2026, below the -$0.30 estimate by 260.00%.
What EPS do analysts expect from LFCR next quarter?
The consensus EPS estimate for Lifecore Biomedical for the quarter ended Sep 30, 2026 is -$0.30 from 4 analysts, with estimates from -$0.33 to -$0.26.
How often does LFCR beat earnings estimates?
Lifecore Biomedical beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -57.03%.
LFCR pages: Overview, Earnings, Forecast, Financials, Competitors